GlassScriptPhysician profile
Christopher G Wilson
NPI 1073136784
$6,118.16
in general payments reported to CMS, 2019-2025
25 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $1,343 · 2023: $1,472 · 2024: $1,391 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,212.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,155.45 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $596.40 | 2021-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $443.33 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $369.07 | 2021-2025 | Gvoke Hypopen |
| Medtronic, INC. | $368.34 | 2021-2025 | Minimed 780g |
| Amgen INC. | $355.39 | 2022-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $230.77 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $230.71 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.85 | 2021-2025 | Jardiance |
| Beta Bionics, INC. | $172.25 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $152.00 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $149.96 | 2021-2024 | |
| Corcept Therapeutics | $127.30 | 2023-2025 | Korlym |
| Averitas Pharma INC. | $91.01 | 2023-2024 | Qutenza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $61.75 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $37.43 | 2025 | Isturisa |
| Nevro Corp. | $30.78 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.27 | 2023 | |
| Sequel Med Tech, LLC | $21.45 | 2025 | Twiist |
| Kyowa Kirin, INC. | $17.85 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.76 | 2025 | |
| Grt US Holding, INC. | $13.20 | 2022 | |
| Merck Sharp & Dohme LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.